These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
108 related articles for article (PubMed ID: 27884221)
1. Hypertension: New and Future Challenges. Frohlich ED Med Clin North Am; 2017 Jan; 101(1):1-6. PubMed ID: 27884221 [TBL] [Abstract][Full Text] [Related]
2. Candesartan: from left ventricular hypertrophy to heart failure, a global approach. Barrios V; Escobar C; Calderon A Expert Rev Cardiovasc Ther; 2007 Sep; 5(5):825-34. PubMed ID: 17867913 [TBL] [Abstract][Full Text] [Related]
3. Mechanisms of development of heart failure in the hypertensive patient. Bristow MR Cardiology; 1999; 92 Suppl 1():3-6; discussion 7-9, 20-1. PubMed ID: 10652966 [TBL] [Abstract][Full Text] [Related]
4. Peritoneal dialysis allows successful cardiac transplantation in patients with refractory heart failure. Quirós-Ganga PL; Remón-Rodríguez C; Tejuca-Marenco M; de la Espada-Piña V Nefrologia; 2015; 35(1):121-4. PubMed ID: 25611845 [No Abstract] [Full Text] [Related]
5. [Pathophysiology of left ventricular hypertrophy in arterial hypertension]. Vallotton MB; Braconi-Quintaje S; Lang U Praxis (Bern 1994); 1997 Feb; 86(7):234-7. PubMed ID: 9139339 [TBL] [Abstract][Full Text] [Related]
7. The role of hypertension in the pathogenesis of heart failure. A clinical mechanistic overview. Vasan RS; Levy D Arch Intern Med; 1996 Sep; 156(16):1789-96. PubMed ID: 8790072 [TBL] [Abstract][Full Text] [Related]
9. The what, why and how of hypertensive heart disease. Weber KT J Hum Hypertens; 1994 Sep; 8(9):665-75. PubMed ID: 7807496 [TBL] [Abstract][Full Text] [Related]
10. K(ATP) activation prevents progression of cardiac hypertrophy to failure induced by pressure overload via protecting endothelial function. Gao S; Long CL; Wang RH; Wang H Cardiovasc Res; 2009 Aug; 83(3):444-56. PubMed ID: 19304734 [TBL] [Abstract][Full Text] [Related]
12. [Left-ventricular hypertrophy as a cardiac risk factor: role of the renin-angiotensin-aldosterone system]. Erne P Praxis (Bern 1994); 1996 Feb; 85(8):227-33. PubMed ID: 8701189 [TBL] [Abstract][Full Text] [Related]
13. From left ventricular hypertrophy to congestive heart failure: management of hypertensive heart disease. Gradman AH; Alfayoumi F Prog Cardiovasc Dis; 2006; 48(5):326-41. PubMed ID: 16627048 [TBL] [Abstract][Full Text] [Related]
14. [Organ damage and cardiorenal syndrome in acute heart failure]. Casado Cerrada J; Pérez Calvo JI Med Clin (Barc); 2014 Mar; 142 Suppl 1():26-31. PubMed ID: 24930080 [TBL] [Abstract][Full Text] [Related]
15. Angiotensin receptor blockers: role in hypertension management, cardiovascular risk reduction, and nephropathy. Basile J; Toth PP South Med J; 2009 Oct; 102(10 Suppl):S1-S12. PubMed ID: 19834426 [TBL] [Abstract][Full Text] [Related]
16. Preventing and reversing target organ damage by treatment of the renin-angiotensin system. Krakoff LR; Rajasekharaiah V Mt Sinai J Med; 1998 Mar; 65(2):125-32. PubMed ID: 9520516 [No Abstract] [Full Text] [Related]
17. Prevention of disease progression, left ventricular hypertrophy and congestive heart failure in hypertension treatment trials. Moser M; Hebert PR J Am Coll Cardiol; 1996 Apr; 27(5):1214-8. PubMed ID: 8609345 [TBL] [Abstract][Full Text] [Related]
18. Should regression or prevention of development of the electrocardiographic strain pattern be an indication for more aggressive treatment in hypertensive patients? Okin PM J Hypertens; 2010 Aug; 28(8):1617-9. PubMed ID: 20647857 [No Abstract] [Full Text] [Related]